Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 24

1.

Pharmacokinetics and tumor localization of (111)in-labeled HuCC49DeltaC(H)2 in BALB/c mice and athymic murine colon carcinoma xenograft.

Chinn PC, Morena RA, Santoro DA, Kazules T, Kashmiri SV, Schlom J, Hanna N, Braslawsky G.

Cancer Biother Radiopharm. 2006 Apr;21(2):106-16.

PMID:
16706631
2.

Novel antibody hinge regions for efficient production of CH2 domain-deleted antibodies.

Glaser SM, Hughes IE, Hopp JR, Hathaway K, Perret D, Reff ME.

J Biol Chem. 2005 Dec 16;280(50):41494-503. Epub 2005 Oct 12.

3.

The structure of an antitumor C(H)2-domain-deleted humanized antibody.

Larson SB, Day JS, Glaser S, Braslawsky G, McPherson A.

J Mol Biol. 2005 May 20;348(5):1177-90. Epub 2005 Apr 1.

PMID:
15854653
4.

Pharmacokinetics and clinical evaluation of 125I-radiolabeled humanized CC49 monoclonal antibody (HuCC49deltaC(H)2) in recurrent and metastatic colorectal cancer patients.

Xiao J, Horst S, Hinkle G, Cao X, Kocak E, Fang J, Young D, Khazaeli M, Agnese D, Sun D, Martin E Jr.

Cancer Biother Radiopharm. 2005 Feb;20(1):16-26.

PMID:
15778575
5.

Pilot study using a humanized CC49 monoclonal antibody (HuCC49DeltaCH2) to localize recurrent colorectal carcinoma.

Agnese DM, Abdessalam SF, Burak WE Jr, Arnold MW, Soble D, Hinkle GH, Young D, Khazaeli MB, Martin EW Jr.

Ann Surg Oncol. 2004 Feb;11(2):197-202.

PMID:
14761924
6.

A novel monoclonal antibody design for radioimmunotherapy.

Forero A, Meredith RF, Khazaeli MB, Carpenter DM, Shen S, Thornton J, Schlom J, LoBuglio AF.

Cancer Biother Radiopharm. 2003 Oct;18(5):751-9.

PMID:
14629823
7.

99mTc-labeled divalent and tetravalent CC49 single-chain Fv's: novel imaging agents for rapid in vivo localization of human colon carcinoma.

Goel A, Baranowska-Kortylewicz J, Hinrichs SH, Wisecarver J, Pavlinkova G, Augustine S, Colcher D, Booth BJ, Batra SK.

J Nucl Med. 2001 Oct;42(10):1519-27.

8.

A CDR-grafted (humanized) domain-deleted antitumor antibody.

Slavin-Chiorini DC, Kashmiri SV, Lee HS, Milenic DE, Poole DJ, Bernon E, Schlom J, Hand PH.

Cancer Biother Radiopharm. 1997 Oct;12(5):305-16.

PMID:
10851481
9.

Correlation of toxicity with treatment parameters for 131I-CC49 radioimmunotherapy in three phase II clinical trials.

Liu T, Meredith RF, Saleh MN, Wheeler RH, Khazaeli MB, Plott WE, Schlom J, LoBuglio AF.

Cancer Biother Radiopharm. 1997 Apr;12(2):79-87.

PMID:
10851451
10.

Biologic properties of a CH2 domain-deleted recombinant immunoglobulin.

Slavin-Chiorini DC, Horan Hand PH, Kashmiri SV, Calvo B, Zaremba S, Schlom J.

Int J Cancer. 1993 Jan 2;53(1):97-103.

PMID:
8416208
11.

Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins.

Slavin-Chiorini DC, Kashmiri SV, Schlom J, Calvo B, Shu LM, Schott ME, Milenic DE, Snoy P, Carrasquillo J, Anderson K, et al.

Cancer Res. 1995 Dec 1;55(23 Suppl):5957s-5967s.

12.

Circulating immune complexes in cancer patients receiving goat radiolocalizing antibodies to carcinoembryonic antigen.

Primus FJ, Bennett SJ, Kim EE, DeLand FH, Zahn MC, Goldenberg DM.

Cancer Res. 1980 Mar;40(3):497-501.

13.

A spectrum of monoclonal antibodies reactive with human mammary tumor cells.

Colcher D, Hand PH, Nuti M, Schlom J.

Proc Natl Acad Sci U S A. 1981 May;78(5):3199-203.

14.

Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3.

Johnson VG, Schlom J, Paterson AJ, Bennett J, Magnani JL, Colcher D.

Cancer Res. 1986 Feb;46(2):850-7.

15.

A radioimmunoassay for the detection of a human tumor-associated glycoprotein (TAG-72) using monoclonal antibody B72.3.

Paterson AJ, Schlom J, Sears HF, Bennett J, Colcher D.

Int J Cancer. 1986 May 15;37(5):659-66.

PMID:
3699929
16.

Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma.

Colcher D, Esteban J, Carrasquillo JA, Sugarbaker P, Reynolds JC, Bryant G, Larson SM, Schlom J.

Cancer Res. 1987 Aug 1;47(15):4218-24. Erratum in: Cancer Res 1987 Nov 15;47(22):6161.

17.

Expression in COS cells of a mouse-human chimaeric B72.3 antibody.

Whittle N, Adair J, Lloyd C, Jenkins L, Devine J, Schlom J, Raubitschek A, Colcher D, Bodmer M.

Protein Eng. 1987 Dec;1(6):499-505.

PMID:
3508296
18.

Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies.

Colcher D, Minelli MF, Roselli M, Muraro R, Simpson-Milenic D, Schlom J.

Cancer Res. 1988 Aug 15;48(16):4597-603.

19.

Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen.

Muraro R, Kuroki M, Wunderlich D, Poole DJ, Colcher D, Thor A, Greiner JW, Simpson JF, Molinolo A, Noguchi P, et al.

Cancer Res. 1988 Aug 15;48(16):4588-96.

20.

Transport of molecules across tumor vasculature.

Jain RK.

Cancer Metastasis Rev. 1987;6(4):559-93. Review.

PMID:
3327633

Supplemental Content

Support Center